Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson, Michael Frenneaux (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

    Original languageEnglish
    Pages (from-to)693-698
    Number of pages6
    JournalFuture Cardiology
    Volume10
    Issue number6
    DOIs
    Publication statusPublished - 1 Nov 2014

    Keywords

    • cardiac spectroscopy
    • diastole
    • ejection fraction
    • heart failure
    • perhexiline

    Fingerprint Dive into the research topics of 'Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome'. Together they form a unique fingerprint.

    Cite this